-
Tytuł:
-
Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
-
Autorzy:
-
Jiang ZF; Department of Respiratory Medicine, National Key Clinical Specialist Construction Programs of China, the First Affiliated Hospital of Anhui Medical University, Jixi Road 218, Hefei 230022, Anhui, PR China. Electronic address: .
Wang M; Department of Respiratory Medicine, Anhui Chest Hospital, Jixi Road 397, Hefei 230022, Anhui, PR China.
Xu JL; Department of Pulmonary, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai 200030, PR China.
-
Źródło:
-
Life sciences [Life Sci] 2018 Feb 01; Vol. 194, pp. 1-6. Date of Electronic Publication: 2017 Dec 14.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Publication: <2008->: Amsterdam : Elsevier
Original Publication: Oxford; Elmsford, N. Y. [etc.] Pergamon Press.
-
MeSH Terms:
-
Antigens, Neoplasm/*blood
Carcinoembryonic Antigen/*blood
Keratin-19/*blood
Lung Neoplasms/*blood
Lung Neoplasms/*diagnosis
Phosphopyruvate Hydratase/*blood
Thymidine Kinase/*blood
Adenocarcinoma/blood ; Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor/blood ; Carcinoma, Non-Small-Cell Lung/blood ; Carcinoma, Squamous Cell/blood ; Female ; Humans ; Male ; Middle Aged ; ROC Curve ; Retrospective Studies
-
Contributed Indexing:
-
Keywords: CEA; CYFRA21-1; Lung cancer; NSE; TK1
-
Substance Nomenclature:
-
0 (Antigens, Neoplasm)
0 (Biomarkers, Tumor)
0 (Carcinoembryonic Antigen)
0 (Keratin-19)
0 (antigen CYFRA21.1)
EC 2.7.1.21 (Thymidine Kinase)
EC 2.7.1.21 (thymidine kinase 1)
EC 4.2.1.11 (Phosphopyruvate Hydratase)
-
Entry Date(s):
-
Date Created: 20171217 Date Completed: 20180213 Latest Revision: 20180213
-
Update Code:
-
20240104
-
DOI:
-
10.1016/j.lfs.2017.12.020
-
PMID:
-
29247745
-
Aims: Thymidine kinase 1 (TK1) is a tumor biomarker in human malignancies. The purpose of this study was to evaluate the diagnostic efficiency of this marker for lung cancer using the combined analysis of carcinoembryonic antigen (CEA), cytokeratin-19 fragment (CYFRA21-1), neuron specific enolase (NSE) and TK1.
Main Methods: From 2013 to 2014, 147 patients with lung cancer and 228 patients with lung benign diseases who were admitted to our hospital were reviewed. Peripheral blood samples were collected for the detection of TK1, CEA, CYFRA21-1 and NSE. The diagnostic value of each marker was analyzed using receiver operating characteristic (ROC) curves and logistic regression equations.
Key Findings: The serum levels of TK1, CEA, CYFRA21-1 and NSE were significantly higher than those in patients with lung benign diseases (all P<0.05). The TK1 concentration was dependent on TNM stage (P=0.005). The ROC curve analyses showed that the diagnostic value of TK1 combined with CEA, CYFRA21-1 and NSE in lung cancer was significantly higher than that of each biomarker alone (all P<0.0001). In addition, TK1 combined with CEA, CYFRA21-1, or NSE could also improve the diagnosis of the squamous cell carcinoma, adenocarcinoma and small cell lung cancer subtypes, respectively.
Significance: The combined detection of TK1 and the other three markers significantly improved the diagnosis of lung cancer. Furthermore, the detection of TK1 combined with that of CYFRA21-1, CEA or NSE increased the diagnostic value of TK1 for lung squamous cell carcinoma, adenocarcinoma and SCLC, respectively.
(Copyright © 2017 Elsevier Inc. All rights reserved.)
